Genta, Sofia; Ghilardi, Guido; Cascione, Luciano; Juskevicius, Darius; Tzankov, Alexandar; Schär, Sämi; Milan, Lisa; Pirosa, Maria Cristina; Esposito, Fabiana; Ruberto, Teresa; Giovanella, Luca; Hayoz, Stefanie; Mamot, Christoph; Dirnhofer, Stefan; Zucca, Emanuele; Ceriani, Luca (2022). Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study. Cancers, 14(4) MDPI AG 10.3390/cancers14041018
|
Text
cancers-14-01018.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (1MB) | Preview |
Accurate estimation of the progression risk after first-line therapy represents an unmet clinical need in diffuse large B-cell lymphoma (DLBCL). Baseline (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) parameters, together with genetic analysis of lymphoma cells, could refine the prediction of treatment failure. We evaluated the combined impact of mutation profiling and baseline PET/CT functional parameters on the outcome of DLBCL patients treated with the R-CHOP14 regimen in the SAKK38/07 clinical trial (NCT00544219). The concomitant presence of mutated SOCS1 with wild-type CREBBP and EP300 defined a group of patients with a favorable prognosis and 2-year progression-free survival (PFS) of 100%. Using an unsupervised recursive partitioning approach, we generated a classification-tree algorithm that predicts treatment outcomes. Patients with elevated metabolic tumor volume (MTV) and high metabolic heterogeneity (MH) (15%) had the highest risk of relapse. Patients with low MTV and favorable mutational profile (9%) had the lowest risk, while the remaining patients constituted the intermediate-risk group (76%). The resulting model stratified patients among three groups with 2-year PFS of 100%, 82%, and 42%, respectively (p < 0.001).
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology |
ISSN: |
2072-6694 |
Publisher: |
MDPI AG |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
01 Mar 2022 16:10 |
Last Modified: |
01 Mar 2022 16:20 |
Publisher DOI: |
10.3390/cancers14041018 |
PubMed ID: |
35205765 |
Uncontrolled Keywords: |
DLBCL PET/CT lymphoma mutational profile prognostic index |
BORIS DOI: |
10.48350/166102 |
URI: |
https://boris.unibe.ch/id/eprint/166102 |
Actions (login required)
 |
Edit item |